Clinical Trials Directory

Trials / Completed

CompletedNCT02547623

Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery

A Phase 3, Prospective, Randomized, Parallel-design, Multicenter Study to Evaluate the Safety of Icon Bioscience-10090 for the Treatment of Inflammation Associated With Cataract Surgery

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
194 (actual)
Sponsor
ICON Bioscience Inc · Industry
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

The study is a prospective, randomized, parallel-design, multicenter trial in patients ≥40 years of age undergoing cataract surgery. Patients who meet all inclusion and no exclusion criteria will be randomized to 1 of 2 treatment groups * A single 5 mcl anterior chamber injection of IBI 10090, 103.4 mcg/mcl dexamethasone, equivalent dexamethasone dose: 517 mcg at the conclusion of cataract surgery or; * Prednisolone acetate ophthalmic suspension 1% eye drops administered 1 drop 4 times daily (QID) for 3 weeks Safety will be assessed by adverse events (AEs), slit lamp biomicroscopy, fundus examination, intraocular pressure (IOP), visual acuity, and specular microscopy endothelial cell count.

Detailed description

The study is a prospective, randomized, parallel-design, multicenter trial in patients ≥40 years of age undergoing cataract surgery. Patients who meet all inclusion and no exclusion criteria will be randomized to 1 of 2 treatment groups * A single 5 mcl anterior chamber injection of IBI 10090, 103.4 mcg/mcl dexamethasone, equivalent dexamethasone dose: 517 mcg at the conclusion of cataract surgery or; * Prednisolone acetate ophthalmic suspension 1% eye drops administered 1 drop 4 times daily (QID) for 3 weeks

Conditions

Interventions

TypeNameDescription
DRUGDexamethasonedepot intracameral
DRUGPrednisolonePrednisolone eye drops 1%

Timeline

Start date
2015-11-06
Primary completion
2016-08-16
Completion
2016-08-16
First posted
2015-09-11
Last updated
2018-08-21
Results posted
2018-06-19

Locations

11 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02547623. Inclusion in this directory is not an endorsement.